Effect of Lanthanum Carbonate in Patients Previously Treated With Calcium-based Phosphate Binder Therapy
NCT01130831 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 66
Last updated 2021-06-28
Summary
To assess the percentage of patients on lanthanum carbonate, that achieve Kidney Disease Outcome Quality Initiative (KDOQI) guideline suggested values for serum phosphorous in patients previously treated with calcium-based phosphate binder therapy.
Conditions
Interventions
- DRUG
-
Lanthanum carbonate
Sponsors & Collaborators
-
Shire
lead INDUSTRY
Principal Investigators
-
Study Director · Takeda
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-04-26
- Primary Completion
- 2012-06-12
- Completion
- 2012-06-12
Countries
- Germany
Study Locations
More Related Trials
-
Outcome Study of Lanthanum Carbonate Compared With Calcium Carbonate in Hemodialysis Patients : Landmark Study
NCT01578200 ·Status: COMPLETED ·Phase: PHASE3
-
Lanthanum Versus Calcium Carbonate for Vascular Abnormalities in Patients With CKD and Hyperphosphatemia
NCT02237534 ·Status: UNKNOWN ·Phase: PHASE4
-
Different Effects of Non-calcium Phosphate Binders on Serum Calcium
NCT03451019 ·Status: COMPLETED ·Phase: PHASE4
-
Calcium Balance Studies in Children With CKD and on Dialysis
NCT03285854 ·Status: UNKNOWN
-
Long-term Treatment on BAY77-1931 (Lanthanum Carbonate) to Measure Lanthanum Concentrations in Bone
NCT00767637 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of Colecalciferol Substitution in Dialysis Patients
NCT00397475 ·Status: COMPLETED ·Phase: NA
-
Hyperphosphatemia in Children With Chronic Kidney Disease
NCT03202407 ·Status: UNKNOWN ·Phase: PHASE3
-
Effect of Sevelamer on Glucose Tolerance and Insulin Sensitivity in Patients With Chronic Renal Failure (CKD)
NCT00837655 ·Status: WITHDRAWN ·Phase: NA
-
Activated Charcoal Use in Chronic Kidney Disease Patients
NCT06906874 ·Status: RECRUITING ·Phase: PHASE2
-
Study of 1.25 mmol/L Calcium Dialysate on Mineral Metabolism in Haemodialysis Patients.
NCT00744302 ·Status: COMPLETED ·Phase: PHASE2
-
Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-1
NCT05832931 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment of Secondary Hyperparathyroidism in the Uremic Patient
NCT00469599 ·Status: TERMINATED ·Phase: NA
-
Trial to Optimize Mineral Outcomes in Dialysis Patients
NCT01100723 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Active Vitamin D and Etelcalcetide on Human Osteoclasts in Patients With Chronic Kidney Disease
NCT03527511 ·Status: COMPLETED
-
Regulation of Bone Formation in Renal Osteodystrophy
NCT00560300 ·Status: COMPLETED ·Phase: PHASE2
-
Nicotinic Acid in Hemodialysis Patients With Hyperphosphatemia
NCT02836184 ·Status: UNKNOWN ·Phase: PHASE4
-
The Effects of Hemodialysis on Serum Sclerostin Levels
NCT03952819 ·Status: COMPLETED
-
Acute Changes in the Mineral Metabolism After a High Phosphorous Containing Meal in Dialysis Patients
NCT03868371 ·Status: COMPLETED ·Phase: NA
-
Supplemented Low Protein Diet and Progression of CKD
NCT03818568 ·Status: COMPLETED ·Phase: NA
-
A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China
NCT06933472 ·Status: RECRUITING ·Phase: PHASE3
-
Use of ETElcalcetidefor pReserving vitamiN K-dependent proteIn activiTY ITAlian Study
NCT06352957 ·Status: NOT_YET_RECRUITING
-
The Effects of Different Dialysate Calcium Concentration
NCT01839383 ·Status: UNKNOWN ·Phase: NA
-
Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol
NCT01725113 ·Status: TERMINATED ·Phase: PHASE4
-
A Study to Follow-up Patients With End Stage Renal Disease Undergoing Hemodialysis, Receiving Selective Vitamin D Receptor Activator's for Prevention and Treatment of Secondary Hyperparathyroidism
NCT01149291 ·Status: COMPLETED
-
The Effect of Increasing Dialysate Magnesium on Calcification Propensity in Subjects on Haemodialysis
NCT02977117 ·Status: COMPLETED ·Phase: PHASE2